Annual operating income of CanSino Biologics Inc. 2017-2021
In 2021, the Chinese vaccine company Cansino Biologics Inc. reported an annual operating income of almost two billion yuan, thanks to the sales of Convidecia, CanSino's single-dose COVID-19 vaccine. The company generated little revenue before the COVID-19 pandemic and suffered from growing losses.